The Latest

  • A illustration of a test tube in front of butterfly wings with molecule shaped wing structure. The butterfly is centered between two profile faces with floating DNA and pills.
    Image attribution tooltip

    Illustration: Vartika Sharma for Industry Dive

    Image attribution tooltip
    Deep Dive // PharmaVoice 100

    The 2024 PharmaVoice 100

    This year’s PharmaVoice 100 encompasses the industry’s ongoing revolutions and leaders who are not only navigating these changes, but at times, forging new paths for others to follow.

  • An illustration of human lungs with a geometrical effect.
    Image attribution tooltip
    eranicle via Getty Images
    Image attribution tooltip
    Q&A

    How AZ’s respiratory wins are ramping up for a bigger prize in COPD

    As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.

  • PV100 category rare disease warriors
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Rare Disease Warriors

    Pharma pros driving drug development and access for patients with high unmet needs. 

  • three people stand behind voting booths
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    Where Big Pharma’s campaign cash is flowing in this election

    Big Pharma CEOs are hedging all bets by supporting both sides of the aisle in the 2024 election.

  • superbugs
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    On the front lines of the superbug war, new treatments can’t arrive soon enough

    As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.

  • Mechanical hand reaching toward clear pill against a backdrop of numerical code
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Tech and AI Wizards

    Digital pioneers harnessing the data to improve pharma’s outcomes.

  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J’s comeback kid Spravato heads for blockbuster status

    After a slow start, the novel esketamine nasal spray for depression is now J&J’s fastest-growing medication.

  • Mergers puzzle
    Image attribution tooltip
    Anton Vierietin / Getty Images via Getty Images
    Image attribution tooltip

    Why pharma megamergers may become a relic of the past

    Despite pent up M&A demand, FTC scrutiny has had a chilling effect on pharma’s appetite for striking major deals.

  • Dengue vax
    Image attribution tooltip
    Buda Mendes via Getty Images
    Image attribution tooltip

    Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next?

    As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.

  • People pass an office building with signage spelling Pfizer in New York City.
    Image attribution tooltip
    George Clerk via Getty Images
    Image attribution tooltip

    With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble

    Pfizer’s proxy battle with Starboard has gotten messy. It’s the latest in a series of activist investor campaigns that have been on the rise in recent years.

  • Biotech pathfinders, PharmaVoice 100
    Image attribution tooltip
    Permission granted by Photo illustration: Industry Dive; Getty Images
    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Biotech Pathfinders

    Leaders solving biology's toughest puzzles and driving innovation forward.

  • Drug injection pens and vials are arranged on a wooden table.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip

    FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage

    After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA changed its mind and re-opened the door for GLP-1 compounders.

  • Hands clasping
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Patient Champions

    Leaders advancing health advocacy, DEI initiatives and better medicine access for patients.

  • Peyton Howell horizontal shot
    Image attribution tooltip
    Permission granted by Parexel
    Image attribution tooltip

    Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with

    From tech-related challenges to an ongoing staffing crunch, Parexel’s CEO explains what the clinical trials industry is up against.

  • Test tube blood
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    As new Alzheimer’s biomarkers come into play, here’s where the money is going

    The Alzheimer’s Drug Discovery Foundation has its finger on the pulse of diagnostics to add precision to the next wave of therapies.

  • heart monitor chart
    Image attribution tooltip
    PharmaVoice/PharmaVoice
    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Cardiometabolic All-Stars

    Leaders tackling long-standing health needs with new solutions.

  • A  3D illustration of ribonucleic acid, or RNA, strands
    Image attribution tooltip
    Christoph Burgstedt via Getty Images
    Image attribution tooltip

    Wave sees RNA editing validation in early trial results

    The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

  • Corporate logos are seen outside  on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    Want to launch a blockbuster? An AstraZeneca exec breaks it down.

    Even drugs with “blockbuster potential” often fall short of expectations. Here’s what can help a new medication pass the $1 billion mark.

  • Google DeepMind Employees Share 2024 Nobel Prize In Chemistry
    Image attribution tooltip
    Dan Kitwood/Getty Images via Getty Images
    Image attribution tooltip

    AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential

    A Nobel Prize in chemistry for Google’s DeepMind protein-structure mapping is the tip of the iceberg for advances in drug discovery and development.

  • PharmaVoice 100 trailblazers
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Trailblazers

    Industry leaders charting new paths in science and business. 

  • Two prescription drug cartons stand side by side on a counter, each bearing the word Wegovy.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.

    Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future. 

  • Donald Trump And VP Kamala Harris At The National Constitution Center In Philadelphia
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    As election day nears, Trump and Harris veer in different directions on pharma

    The two presidential candidates have developed diverging policies related to healthcare and pharma.

  • Ryan Douglas, co-founder and chairman, DeepWell Digital Therapeutics
    Image attribution tooltip
    Permission granted by DeepWell
    Image attribution tooltip

    Will a Medicare boost propel digital therapeutics to the mainstream?

    Digital therapeutics have languished in the background of traditional medicines for years, but a recent reimbursement push may have gotten the ball rolling.

  • Microscope blood slide
    Image attribution tooltip
    Motortion via Getty Images
    Image attribution tooltip

    Regeneron takes the long-haul approach to oncology, stumbles and all

    Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.

  • Silhouette of people in business attire in front of a wall of windows
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    2024 PharmaVoice 100s: Standout Leaders

    Long-time executives with a strong track record of advancing drug R&D, business savvy strategies and leadership in various sectors of pharma.